152 related articles for article (PubMed ID: 17787038)
1. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity.
Davis PM; Abraham R; Xu L; Nadler SG; Suchard SJ
J Rheumatol; 2007 Nov; 34(11):2204-10. PubMed ID: 17787038
[TBL] [Abstract][Full Text] [Related]
2. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
3. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
4. Human monocyte-mediated cytotoxicity: the use of Ig-bearing hybridomas as target cells to detect trigger molecules on the monocyte cell surface.
Graziano RF; Fanger MW
J Immunol; 1987 Feb; 138(3):945-50. PubMed ID: 2949010
[TBL] [Abstract][Full Text] [Related]
5. Separation of cell-dependent antibody (CDA) and inhibitory antibody by protein-A affinity chromatography and the effect of fractions on antibody-dependent cellular cytotoxicity (ADCC).
Sato N; Yabuki Y; Toh K; Ishii Y; Kikuchi K
Immunology; 1979 Mar; 36(3):421-6. PubMed ID: 437836
[TBL] [Abstract][Full Text] [Related]
6. Effect of recombinant IFN-gamma (rIFN-gamma) on the mechanism of human macrophage IgG FcRI-mediated cytotoxicity. rIFN-gamma decreases inhibition by cytophilic human IgG and changes the cytolytic mechanism.
Van Schie RC; Verstraten RG; Van de Winkel JG; Tax WJ; de Mulder PH
J Immunol; 1992 Jan; 148(1):169-76. PubMed ID: 1530794
[TBL] [Abstract][Full Text] [Related]
7. Role of low-affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages.
Munn DH; McBride M; Cheung NK
Cancer Res; 1991 Feb; 51(4):1117-23. PubMed ID: 1825476
[TBL] [Abstract][Full Text] [Related]
8. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
Hodoniczky J; Zheng YZ; James DC
Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
[TBL] [Abstract][Full Text] [Related]
9. High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism.
Mishima Y; Terui Y; Mishima Y; Kuniyoshi R; Matsusaka S; Mikuniya M; Kojima K; Hatake K
Int Immunol; 2012 Aug; 24(8):477-83. PubMed ID: 22438420
[TBL] [Abstract][Full Text] [Related]
10. Methods to measure the binding of therapeutic monoclonal antibodies to the human Fc receptor FcγRIII (CD16) using real time kinetic analysis and flow cytometry.
Harrison A; Liu Z; Makweche S; Maskell K; Qi H; Hale G
J Pharm Biomed Anal; 2012 Apr; 63():23-8. PubMed ID: 22366323
[TBL] [Abstract][Full Text] [Related]
11. The mononuclear cell in human blood which mediates antibody-dependent cellular cytotoxicity to virus-infected target cells. II. Identification as a K cell.
Melewicz FM; Shore SL; Ades EW; Phillips DJ
J Immunol; 1977 Feb; 118(2):567-73. PubMed ID: 65428
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
[TBL] [Abstract][Full Text] [Related]
13. Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn.
Bernett MJ; Chu SY; Leung I; Moore GL; Lee SH; Pong E; Chen H; Phung S; Muchhal US; Horton HM; Lazar GA; Desjarlais JR; Szymkowski DE
MAbs; 2013; 5(3):384-96. PubMed ID: 23549103
[TBL] [Abstract][Full Text] [Related]
14. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
[TBL] [Abstract][Full Text] [Related]
15. In vitro cell-mediated cytotoxicity in primary biliary cirrhosis and chronic hepatitis. Dysfunction of spontaneous cell-mediated cytotoxicity in primary biliary cirrhosis.
Vierling JM; Nelson DL; Strober W; Bundy DM; Jones EA
J Clin Invest; 1977 Nov; 60(5):1116-28. PubMed ID: 332716
[TBL] [Abstract][Full Text] [Related]
16. The functional activity of Fc gamma RII and Fc gamma RIII on subsets of human lymphocytes.
Hadley AG; Zupanska B; Kumpel BM; Leader KA
Immunology; 1992 Jul; 76(3):446-51. PubMed ID: 1356095
[TBL] [Abstract][Full Text] [Related]
17. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
[TBL] [Abstract][Full Text] [Related]
18. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
van Meerten T; van Rijn RS; Hol S; Hagenbeek A; Ebeling SB
Clin Cancer Res; 2006 Jul; 12(13):4027-35. PubMed ID: 16818702
[TBL] [Abstract][Full Text] [Related]
19. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
Woodhouse CS; Morgan AC
Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860
[TBL] [Abstract][Full Text] [Related]
20. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
